Health GlobalData found that the products currently in the market are highly efficacious in providing protection against meningitis with minimal side-effects. All the marketed products provide high seroprotection rates and seroconversion rates against the disease. The key products, such as Menactra, ActHIB, Merrem,AmBisome, the Menjugate vaccine and Meningitec vaccine, are able to satisfy the demands of treated patients. Despite being highly competitive, the meningitis market holds significant opportunities for any new entrants as there is no single vaccine or therapy that is available globally to protect all age groups,and there is untapped market potential for the treatment of the MenACW-135Y and MenB serogroups. The meningitis market has very low unmet needs, as the market is well served by the current product options available. This leaves little scope for new entrants to capture value from under-served segments.The new products have to aim at gaining market share by providing unique offerings and targeting niche segments. The most likely to be under-served segments are those people suffering with the MenACW-135Y and MenB serogroups. The current pipeline, however, is strong enough to cater to this unmet need. For further details, please click or add the below link to your browser: .www.globaldata.com/reportstore/Report.aspx?ID=Meningitis-Preventive-Vaccines-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare GlobalData has found that the product pipeline for meningitis is strong, with 35 molecules in various phases of clinical development. There are 10 molecules in Phase III, 11 in Phase II and 12 molecules undergoing Phase I clinical trials. A large portion of these are vaccines are more safe and efficacious than the currently marketed products, with novel development procedures or routes of administration. They target the small unmet need that exists in the market. They will compete with the well established vaccines and are likely to redefine the competitive landscape in the market. GlobalData predicts that Novartis, GlaxoSmithKline (GSK), Sanofi-aventis (Sanofi Pasteur) and Merck will remain as the leading competitors in the global meningitis market. New entrants into the market will have to compete mostly on the pricing of their products as the unmet need in the market is quite low. GlobalData estimated the global meningitis preventive vaccine market to be worth $1.8 billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 12% to reach $4.5 billion by 2017. This high growth forecast is primarily attributed to increases in the vaccination seeking population as a result of the increasing world population, increased disease awareness and wider government immunization recommendations. This growth will be supported by the increased production capacities of companies to cater for rising demand. The strong product pipelines of these companies will complement the existing products by providing more effective options to people. For further details, please click or add the below link to your browser: .www.globaldata.com/reportstore/Report.aspx?ID=Meningitis-Preventive-Vaccines-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare Visit our report store: .www.globaldata.com For more details contact: [email protected] North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782 About the Author: GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. Article Published On: ..articlesnatch.. – Health 相关的主题文章:

 

Comments are closed.



Copyright by lilingxiao.com